http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102294025-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6cb4ab729c5c94a203059e5d3f32dbeb |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 |
| filingDate | 2011-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4d3d3ba7c351d7eaeb1a18e7aa72666 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f79d2ecf923d51c188062ea6fd9271e5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60d678ad0f84ddc62ee9a4960342d887 |
| publicationDate | 2013-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102294025-B |
| titleOfInvention | Compound of prostate stem cell antigen polypeptide and nucleic acid and preparation method and application thereof |
| abstract | The invention discloses a compound of PSCA (Prostate Stem Cell Antigen) polypeptide and nucleic acid, which is a granular compound obtained by the way that through positive and negative charge attraction, a PSCA gene recombination eukaryotic expression vector is packaged by fusogenic peptide formed by a positive ion peptide DNA (Deoxyribonucleic Acid) transport carrier and HLA-A2 limit CTL (Cytotoxic T Lymphocyte) epitope peptide PSCA 14-22. The preparation method comprises the steps that in buffer salt solution with pH of 7.2-7.6, the fusogenic peptide and the PSCA gene recombination eukaryotic expression vector are added according to a certain positive and negative charge ratio, are then mixed, and are left standing under room temperature for 0.5-1.5 hours to obtain the compound; the compound is not only combined with the advantages of DNA vaccine and epitope peptide vaccine, but also can imitate natural virus to directly 'infect' APC (Antigen Presenting Cell) and other immune cells, so as to stimulate strong CTL response in vivo. The compound is expected to break down selftolerance of tumour antigen, can be used to prepare prostate cancer therapeutic vaccine of more than 50 % of population in China, and has potential and good development and application prospect in the prostate cancer immunization therapy field. |
| priorityDate | 2011-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 148.